Linked e-resources
Details
Table of Contents
Intro; Contents; Part I: Pathophysiology; 1: Chronic Lymphocytic Leukemia: Who, How, and Where?; 1.1 Introduction; 1.2 Who; 1.2.1 Genetic Predisposition to CLL; 1.2.2 Monoclonal B-Cell Lymphocytosis; 1.2.3 Cell of Origin; 1.3 How; 1.3.1 Mechanisms of Leukemogenesis; 1.3.2 Genetic Defects; 1.3.3 B-Cell Receptor; 1.4 Where; 1.4.1 Microenvironmental Stimuli; 1.4.2 Cellular Components; 1.5 Conclusions; References; Part II: Diagnostics; 2: Laboratory Diagnosis of Chronic Lymphocytic Leukaemia; 2.1 Introduction; 2.2 Full/Complete Blood Count; 2.3 Morphology; 2.4 Immunophenotype
2.5 CLL Diagnostic Algorithms Based on Immunophenotype 2.5.1 CLL Scoring Systems; 2.5.2 ERIC/ESCCA Approach to Improving Diagnostic Reproducibility; 2.6 Molecular Diagnostics; 2.6.1 Chromosomal Deletions and Aneuploidy; 2.6.2 Chromosomal Translocations; 2.6.3 The Immunoglobulin Gene; 2.6.4 Other Molecular Abnormalities; 2.7 Differential Diagnosis; 2.7.1 Mantle Cell Lymphoma; 2.7.2 B-Prolymphocytic Leukaemia; 2.7.3 Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma; 2.7.4 Cold Agglutinin Disease (CAD); 2.7.5 Monoclonal B-Cell Lymphocytosis
2.8 Richter's Syndrome/Large Cell Transformation 2.9 Summary; References; Part III: Clinical Presentation; 3: The Clinical Presentation of CLL; 3.1 Introduction; 3.2 Demographics; 3.2.1 Incidence; 3.2.2 Age Distribution; 3.2.3 Gender; 3.3 Clinical Features; 3.3.1 Presentation; 3.3.2 Lymphoid Involvement; 3.3.3 Extramedullary Features; 3.3.4 Constitutional Symptoms; 3.3.5 Second Malignancies; 3.4 Laboratory Investigations; 3.4.1 Full Blood Count; 3.4.2 Other Blood Tests; 3.4.3 Bone Marrow (BM) Examination; 3.4.4 Imaging Tests; 3.4.5 Cytogenetics/Molecular Investigations
4.3.9.1 Recurrent Acquired Single Nucleotide Variants (SNV) in CLLNOTCH1; SF3B1; 4.3.9.2 Hierarchical Model Integrating Prognostic Information from Genomic Studies; 4.3.9.3 Predicting the Risk of High-Grade Transformation; 4.4 Prognostic Markers in the Era of Novel Therapies; 4.5 Outlook; References; Part V: Treatment; 5: Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Chronic Lymphocytic Leukemia: The 2018 Update; 5.1 Introduction; 5.2 Clinical Relevance of Genetic or Genomic Alterations Found in CLL, Including Mutations of the TP53 Gene
2.5 CLL Diagnostic Algorithms Based on Immunophenotype 2.5.1 CLL Scoring Systems; 2.5.2 ERIC/ESCCA Approach to Improving Diagnostic Reproducibility; 2.6 Molecular Diagnostics; 2.6.1 Chromosomal Deletions and Aneuploidy; 2.6.2 Chromosomal Translocations; 2.6.3 The Immunoglobulin Gene; 2.6.4 Other Molecular Abnormalities; 2.7 Differential Diagnosis; 2.7.1 Mantle Cell Lymphoma; 2.7.2 B-Prolymphocytic Leukaemia; 2.7.3 Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma; 2.7.4 Cold Agglutinin Disease (CAD); 2.7.5 Monoclonal B-Cell Lymphocytosis
2.8 Richter's Syndrome/Large Cell Transformation 2.9 Summary; References; Part III: Clinical Presentation; 3: The Clinical Presentation of CLL; 3.1 Introduction; 3.2 Demographics; 3.2.1 Incidence; 3.2.2 Age Distribution; 3.2.3 Gender; 3.3 Clinical Features; 3.3.1 Presentation; 3.3.2 Lymphoid Involvement; 3.3.3 Extramedullary Features; 3.3.4 Constitutional Symptoms; 3.3.5 Second Malignancies; 3.4 Laboratory Investigations; 3.4.1 Full Blood Count; 3.4.2 Other Blood Tests; 3.4.3 Bone Marrow (BM) Examination; 3.4.4 Imaging Tests; 3.4.5 Cytogenetics/Molecular Investigations
4.3.9.1 Recurrent Acquired Single Nucleotide Variants (SNV) in CLLNOTCH1; SF3B1; 4.3.9.2 Hierarchical Model Integrating Prognostic Information from Genomic Studies; 4.3.9.3 Predicting the Risk of High-Grade Transformation; 4.4 Prognostic Markers in the Era of Novel Therapies; 4.5 Outlook; References; Part V: Treatment; 5: Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Chronic Lymphocytic Leukemia: The 2018 Update; 5.1 Introduction; 5.2 Clinical Relevance of Genetic or Genomic Alterations Found in CLL, Including Mutations of the TP53 Gene